Subscribe to Search results

Dr Aronstam stated that Treloar's patients had already had five different types of concentrates and he prefered not to "confine [himself] to a single Concentrate."

Published on:

Dr Rizza suggested that some of the Treloar's pupils, if possible, should receive NHS material.

Published on:

Dr Aronstam wrote that prophylaxis was "much more effective given on alternate days than twice weekly".

Published on:

Dr Aronstam stated that he had not seen hard data to prove the benefits of lower doses of Factor 8.

Published on:

Dr Aronstam stated "we only give prophylaxis in short courses here and only when a particular joint is being threatened. I am afraid we do not have the resources to give any of our 55 severe haemophiliac boys a long course of prophylaxis just because of bleeding frequency".

Published on:

The chief executive of Speywood stated that Dr Aronstam's "first requirement is convenience of administration" when deciding what treatment to provide to Treloar's students.

Published on:

Dr Kirk provided information in 1976 to the Bournemouth Department of Pathology about a pupil who was negative for HbsAg and HBsAb and had a presumptive diagnosis of non-B hepatitis "probably associated with the transfusion of Kryobulin".

Published on:

Dr Painter spoke to some parents in early 1978, and appeared to regard Hepatitis B which had become chronic as potentially leading to a grim future, and a matter of significant concern.

Published on:

Dr Craske highlighted to Dr Aromstam that mixing the blood products of different manufacturers might increase the risks of hepatitis and advised that it might be wise to confine students to one type of material.

Published on:

Dr Craske asked for people with mild haemophilia to be given NHS Factor 8 for non-urgent operations such as tooth extraction, saying "We have found from observations at Oxford that this is the best way of finding out whether the material is associated with cases of hepatitis".

Published on:

Dr Aronstam disagreed with giving mild haemophiliacs NHS Factor 8 for non-urgent operations as he didn't want them to develop hepatitis in any form.

Published on:

Dr Craske suggested a trial of NHS concentrate be made to cover non-urgent operations, where other concentrates such as commercial material would be indicated.

Published on:

At the 17th meeting of the Haemophilia Reference Centre Directors, at which Dr Aronstam was present, the increased use of cryoprecipitate was discussed in the light of the first known death of a haemophiliac in the UK from AIDS.

Published on:

Dr Aronstam switched from using unheated commercial product to using heat treated commercial product (although he continued to use unheat-treated NHS concentrate).

Published on:

Dr Aronstam informed Dr Ahmed a patient had lost movement in both of his elbows and shoulders as a direct consequence of him not treating himself properly due to a fear of contracting AIDS, recording that he had advised the patient of "the very small risk numerically" of him acquiring the disease.

Published on:

In a letter to Dr Barnes, Dr Aronstam discussed concerns raised by Dr Barnes about Factor VIII affecting "T" cells, noting that the risk was very small and should not deflect from providing appropriate treatment.

Published on:

Dr Aronstam wrote to Dr Snape to enquire about a specially accredited pool of Factor 8 donors for new and mild haemophiliacs.

Published on:

Dr Snape wrote to Dr Lane discussing a letter from Dr Aronstam regarding the use of hepatitis-reduced Factor 8 where he highlights his immediate concern being securing Factor 8 for two untreated babies, additionally, he was prepared to enter suitable pupils from the College for a prospective hepatitis-reduced product study.

Published on:

Dr Aronstam wrote to Professor Bloom confirming that a patient was on the accredited donor pool long before heat treatment became available, it was also confirmed that the patient remained HTLV-3 antibody free.

Published on:

Dr Aronstam expressed reservations as to whether it was ethically right in "the current climate" to continue a patients's tolerance inducing protocol.

Published on: